Nanotechnology for Targeted Inflammatory Bowel Disease Therapy: Challenges and Opportunities

ABSTRACT Inflammatory bowel disease (IBD) is a complex and recurring inflammatory disorder that affects the gastrointestinal tract and is influenced by genetic predisposition, immune dysregulation, the gut microbiota, and environmental factors. Advanced therapies, such as biologics and small molecules, target diverse immune pathways to manage IBD. Nanoparticle (NP)‐based drugs have emerged as effective tools, offering controlled drug release and targeted delivery. This review highlights NP modifications for anti‐inflammatory purposes, utilizing changes such as those in size, charge, redox reactions, and ligand–receptor interactions in drug delivery systems. By using pathological and microenvironmental cues to guide NP design, precise targeting can be achieved. In IBD, a crucial aspect of NP intervention is targeting specific types of cells, such as immune and epithelial cells, to address compromised intestinal barrier function and reduce overactive immune responses. This review also addresses current challenges and future prospects, with the goal of advancing the development of NP‐mediated strategies for IBD treatment.